Abstract
Abstract:The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhibitor, was reviewed in a large population of patients with Parkinson’s disease. All records were reviewed from a Parkinson’s disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine. Patient characteristics, duration and dose of treatment, side effects and reasons for discontinuation were noted. Twenty-three patients received both medications at the same time. No additional side effects were noted with the combination therapy that had not already been reported with each medication alone. No serious side effects were found. In this clinic population, fluoxetine and selegiline were used in combination without major side effects, but further observation is warranted.
Publisher
Cambridge University Press (CUP)
Subject
Neurology (clinical),Neurology,General Medicine
Reference19 articles.
1. Potential fluoxetine-selegiline interaction;Hughes;Ann Pharmacotherapy,1992
2. Fluoxetine relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression;Beasley;Psychopharmacol Bull,1990
3. Altered serotonin metabolism in depressed patients with Parkinson's disease
4. Strategies for fluoxetine-MAOI combination therapy;Peterson;J Clin Psychiatry,1991
5. Fluoxetine and extrapyramidal side effects;Bouchard;Am J Psychiatry,1989
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Serotonin Syndrome;Movement Disorder Emergencies;2021-10-03
2. Movement Disorders;Medical Clinics of North America;2016-07
3. Monoamine Reuptake Inhibitors in Parkinson’s Disease;Parkinson's Disease;2015
4. A Clinician’s Guide to Monoamine Oxidase Inhibitors;Current Psychiatry Reviews;2013-08-31
5. Serotonin Syndrome;Movement Disorder Emergencies;2012-10-16